Abstract: Objective To estimate p53 Arg72Pro polymorphism and their relationship with clinicopathological characteristics and prognosis in lung cancer.
Methods Such databases as PubMed， CNKI， Wanfang and Weipu were searched from the date of their establishment to December 20th，2013 to collect the researches about p53 Arg72Pro polymorphism and their relationship with clinicopathological features and prognosis in lung cancer. According to the inclusion and exclusion criteria， two reviewers independently screened literatures， extracted data and assessed the quality of included studies. Then results of metaanalysis were conducted using RevMan 50 software to calculate crude odds ratio（OR） with their 95% confidence interval（95%CI）. Results A total of 11 researches involving 2730 patients were included. The results of metaanalysis suggested that， the distribution frequency of p53 codon72 Arg／Arg or Arg／Pro in male patients with lung cancer was higher than that in female patients with statistic significance（OR=1.58， 95％CI：1.04-2.40，P=0.03）. The distribution frequency of p53 codon72 Pro／Pro genotypes in lung nonsquamous cell carcinoma was significantly higher than that in lung squamous cell carcinoma（OR=0.69，95％CI：0.49-0.97， P=0.03）. p53 Arg72Pro polymorphism was irrelative with smoking history， clinical stages and 3year survival rate of lung cancer patients. Conclusion p53 Arg72Pro polymorphism is irrelative with prognosis of lung cancer patients. For the quality and quantity limitation of the included studies which decreases the level of evidence， so the conclusion of this systematic review only provides some references for clinical research and practice.